Experimental Gel Could Prevent Genital Herpes Infection: WEDNESDAY.
The new study took place in South Africa, one of those hardest-hit countries. The gel, which contains a medication called tenofovir, is experimental still, stressed study leader Dr. Salim Abdool Karim, director of the guts for the AIDS System of Study, in Durban, South Africa. Further research will probably be necessary for drug regulators in various countries to consider approving the medication, Karim said. The current trial had not been made to test tenofovir gel against HSV-2 primarily; its main aim was to curb the chance of HIV transmission. The oral formulation of tenofovir, which is normally marketed as Viread, is already used to take care of HIV, the virus that causes AIDS. Earlier outcomes from the trial had suggested the gel version can reduce women’s threat of contracting HIV. However, follow-up analysis yielded disappointing results – – generally because many women were not able to use the gel consistently.High PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four occasions higher level of stent thrombosis than sufferers without high platelet reactivity, as seen in the ADAPT-DES registry. The 30-time results from the 8,500+ individual registry were presented today at the 2011 TCT conference in San Francisco. Related StoriesBirmingham experts identify how Salmonella infections can result in life-threatening thrombosisNew approach helps create virtual versions for treating stomach aortic aneurysmsReview of haemodynamics in stent advancement shows spiral flow could be essential to enhancing peripheral arterial stent functionality Stent thrombosis is certainly a uncommon but catastrophic event that sufferers are in risk for following a stent process, stated Dr.